Cargando…

Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

BACKGROUND: Development of resistance to therapy continues to be a serious clinical problem in lung cancer management. We previously identified that Annexin A2 is significantly up-regulated in cisplatin-resistant non-small cell lung cancer (NSCLC) A549/DDP cells. However, the exact function and mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Xiaomin, Liu, Hao, Zhang, Zhijie, Gu, Yixue, Qiu, Huisi, He, Zhimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591524/ https://www.ncbi.nlm.nih.gov/pubmed/28886730 http://dx.doi.org/10.1186/s13046-017-0594-1

Ejemplares similares

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
por: Liu, Hao, et al.
Publicado: (2015)

Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1)
por: Gu, Yixue, et al.
Publicado: (2017)

TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer
por: Jia, Xiaoting, et al.
Publicado: (2017)

TRIB2 contributes to cisplatin resistance in small cell lung cancer
por: Liang, Yuanxin, et al.
Publicado: (2017)

Microarray-Assisted Pathway Analysis Identifies MT1X & NFκB as Mediators of TCRP1-Associated Resistance to Cisplatin in Oral Squamous Cell Carcinoma
por: Peng, Bo, et al.
Publicado: (2012)

TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a
por: Liu, Hao, et al.
Publicado: (2022)

Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2
por: Pang, Linrong, et al.
Publicado: (2017)

WP1130 attenuates cisplatin resistance by decreasing P53 expression in non–small cell lung carcinomas
por: Wang, Xiang, et al.
Publicado: (2017)

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway
por: Lin, Zhilai, et al.
Publicado: (2020)

Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer
por: Cui, Yong, et al.
Publicado: (2018)

Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma
por: Ağababaoğlu, İsmail, et al.
Publicado: (2017)

Annexin A1 is a potential biomarker of bone metastasis in small cell lung cancer
por: Chen, Peng, et al.
Publicado: (2021)

TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway
por: Xing, Ying, et al.
Publicado: (2018)

Store-Operated Calcium Entry Contributes to Cisplatin-Induced Cell Death in Non-Small Cell Lung Carcinoma
por: Gualdani, Roberta, et al.
Publicado: (2019)

Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals
por: Zhou, Pengjun, et al.
Publicado: (2017)

Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor
por: Tang, Jiyang, et al.
Publicado: (2023)

Long Noncoding RNAs Coregulated by Annexin A7 and JNK in Hepatocellular Carcinoma Cells Identified by Whole-Genome Expression Profiling
por: Deng, Qi, et al.
Publicado: (2020)

Dexamethasone Reduces Sensitivity to Cisplatin by Blunting p53-Dependent Cellular Senescence in Non-Small Cell Lung Cancer
por: Ge, Haiyan, et al.
Publicado: (2012)

Angiostrongylus cantonensis Galectin-1 interacts with Annexin A2 to impair the viability of macrophages via activating JNK pathway
por: Shi, Xiaomeng, et al.
Publicado: (2020)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
por: Sun, Chao-Yue, et al.
Publicado: (2018)

Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma: Erratum
Publicado: (2017)

Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis
por: Zeng, Wenjuan, et al.
Publicado: (2021)

Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals
por: Zhou, Pengjun, et al.
Publicado: (2021)

Annexin A7 and JNK knockdown suppress the lymphatic metastasis potential of hepatocellular carcinoma cells: Possible contributions of ATF2 and sequence-related lncRNA NONMMUT114121.1
por: Deng, Qi, et al.
Publicado: (2021)

Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway
por: Chen, Qianqian, et al.
Publicado: (2022)

Annexin A3 Knockdown Suppresses Lung Adenocarcinoma
por: Liu, Ying-Fu, et al.
Publicado: (2016)

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways
por: Cheng, J, et al.
Publicado: (2014)

Annexin A5 as a New Potential Biomarker for Cisplatin-Induced Toxicity in Human Kidney Epithelial Cells
por: Kwon, Yeo-Jung, et al.
Publicado: (2013)

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011)

FUT2 Facilitates Autophagy and Suppresses Apoptosis via p53 and JNK Signaling in Lung Adenocarcinoma Cells
por: Zhang, Yuqi, et al.
Publicado: (2022)

Encephalomyocarditis Virus 2A Protein Inhibited Apoptosis by Interaction with Annexin A2 through JNK/c-Jun Pathway
por: Han, Ruochan, et al.
Publicado: (2022)

Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma
por: Gao, Ya-Ping, et al.
Publicado: (2021)

Smoke-induced SAV1 Gene Promoter Hypermethylation Disrupts YAP Negative Feedback and Promotes Malignant Progression of Non-small Cell Lung Cancer
por: Liu, Ting, et al.
Publicado: (2022)

Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer
por: Ma, Ying, et al.
Publicado: (2023)

p53 Affects PGC1α Stability Through AKT/GSK-3β to Enhance Cisplatin Sensitivity in Non-Small Cell Lung Cancer
por: Deng, Xinyue, et al.
Publicado: (2020)

Upregulation of Acetylcholinesterase Mediated by p53 Contributes to Cisplatin-Induced Apoptosis in Human Breast Cancer Cell
por: Ye, Xiaolei, et al.
Publicado: (2015)

Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
por: Pan, Chun-Hao, et al.
Publicado: (2016)

Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008)

miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma
por: Gu, Yixue, et al.
Publicado: (2018)

The Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells
por: Chuang, Min-Chun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8eeeffpeedise8qkmkoj5j9e8s